DE69833779D1 - Verfahren und zusammensetzungen zur immunomodulation - Google Patents

Verfahren und zusammensetzungen zur immunomodulation

Info

Publication number
DE69833779D1
DE69833779D1 DE69833779T DE69833779T DE69833779D1 DE 69833779 D1 DE69833779 D1 DE 69833779D1 DE 69833779 T DE69833779 T DE 69833779T DE 69833779 T DE69833779 T DE 69833779T DE 69833779 D1 DE69833779 D1 DE 69833779D1
Authority
DE
Germany
Prior art keywords
methods
compositions
protein
useful
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69833779T
Other languages
English (en)
Other versions
DE69833779T2 (de
Inventor
M Gorczynski
A Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trillium Therapeutics ULC
Original Assignee
Trillium Therapeutics ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22058127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69833779(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Trillium Therapeutics ULC filed Critical Trillium Therapeutics ULC
Publication of DE69833779D1 publication Critical patent/DE69833779D1/de
Application granted granted Critical
Publication of DE69833779T2 publication Critical patent/DE69833779T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
DE69833779T 1997-11-07 1998-11-06 Verfahren und zusammensetzungen zur immunomodulation Expired - Lifetime DE69833779T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6476497P 1997-11-07 1997-11-07
US64764P 1997-11-07
PCT/CA1998/001038 WO1999024565A1 (en) 1997-11-07 1998-11-06 Methods and compositions for immunomodulation

Publications (2)

Publication Number Publication Date
DE69833779D1 true DE69833779D1 (de) 2006-05-04
DE69833779T2 DE69833779T2 (de) 2006-11-30

Family

ID=22058127

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69833779T Expired - Lifetime DE69833779T2 (de) 1997-11-07 1998-11-06 Verfahren und zusammensetzungen zur immunomodulation

Country Status (13)

Country Link
US (6) US6338851B1 (de)
EP (1) EP1032662B1 (de)
JP (2) JP4584447B2 (de)
AT (1) ATE319825T1 (de)
AU (1) AU748587B2 (de)
CA (1) CA2308765C (de)
CY (1) CY1105364T1 (de)
DE (1) DE69833779T2 (de)
DK (1) DK1032662T3 (de)
ES (1) ES2260852T3 (de)
HK (1) HK1030625A1 (de)
PT (1) PT1032662E (de)
WO (1) WO1999024565A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6955811B2 (en) 1997-11-07 2005-10-18 Trillium Therapeutics Inc. Methods of inhibiting immune response suppression by administering antibodies to OX-2
US7223729B2 (en) 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
ES2260852T3 (es) 1997-11-07 2006-11-01 Trillium Therapeutics Inc. Metodos y composiciones para inmunomodulacion.
US20020192215A1 (en) * 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
JP2002541210A (ja) * 1999-04-13 2002-12-03 シェーリング コーポレイション 哺乳動物ｏｘ２タンパク質および関連試薬の新規な使用
US6613327B1 (en) * 1999-07-28 2003-09-02 Genetics Institute, Inc. Methods of preventing immune-mediated abortion by inhibiting a CD28-mediated costimulatory signal
WO2001068697A2 (en) * 2000-03-17 2001-09-20 Gorczynski Reginald M Methods and compositions for immunoregulation
WO2001080880A2 (de) * 2000-04-22 2001-11-01 Stefan Barth Apoptotika
CA2417874C (en) * 2000-08-03 2012-10-02 Transplantation Technologies Inc. Use of ox-2 inhibitors for the treatment of cancer
AUPR069500A0 (en) 2000-10-11 2000-11-09 Coster, Douglas John Tissue modification
AU2002223338B2 (en) * 2000-11-22 2007-06-07 Trillium Therapeutics Inc. Truncated CD200
US7427665B2 (en) 2000-12-08 2008-09-23 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line
US20040198661A1 (en) * 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US9249229B2 (en) 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US6906237B2 (en) * 2001-02-27 2005-06-14 G. Scott Herron Vivo assay for anti angiogenic compounds
JP2005511012A (ja) 2001-08-10 2005-04-28 セローノ ジェネティクス インスティテュート ソシエテ アノニム ヒトｃＤＮＡおよびタンパク質およびその使用
EP1439857B1 (de) * 2001-10-12 2009-02-25 Schering Corporation VERWENDUNG VON BISPEZIFISCHEN ANTIKÖRPERN GEGEN EINEN AKTIVIERENDEN REZEPTOR FcEpsilonRI UND GEGEN EINEN INHIBIERENDEN REZEPTOR OX2Ra (CD200Ra) ZUR REGULIERUNG DER IMMUNANTWORTEN
US7196243B2 (en) 2002-04-03 2007-03-27 Trillium Therapeutics Inc. Transgenic animal containing CD200 and uses therefor
WO2004060295A2 (en) * 2002-12-27 2004-07-22 Schering Corporation Methods of inducing and maintaining immune tolerance
CA2601623C (en) 2005-03-14 2018-10-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for evaluating graft survival in a solid organ transplant recipient
USRE46843E1 (en) 2005-03-14 2018-05-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for evaluating graft survival in a solid organ transplant recipient
GB0506721D0 (en) * 2005-04-01 2005-05-11 Univ Glasgow Soluble immunoregulatory factor
DK2463305T3 (en) 2006-01-12 2016-08-29 Alexion Pharma Inc Antibodies to OX-2 / CD200 and uses thereof
WO2008085963A1 (en) * 2007-01-05 2008-07-17 University Of Florida Research Foundation, Inc. Materials and methods for the detection, prevention and treatment of autoimmune disease
US8252285B2 (en) * 2007-07-25 2012-08-28 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof in inhibiting immune responses
US8986684B2 (en) 2007-07-25 2015-03-24 Alexion Pharmaceuticals, Inc. Methods and compositions for treating autoimmune disease
ES2492498T3 (es) * 2009-01-15 2014-09-09 The Board Of Trustees Of The Leland Stanford Junior University Panel de biomarcadores para el diagnóstico y la predicción de rechazo de injerto
WO2011068829A1 (en) 2009-12-02 2011-06-09 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers for determining an allograft tolerant phenotype
SG182408A1 (en) 2010-01-11 2012-08-30 Alexion Pharma Inc Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
WO2011100538A1 (en) 2010-02-11 2011-08-18 Alexion Pharmaceuticals, Inc. Therapeutic methods using an ti-cd200 antibodies
US8846603B2 (en) 2010-03-12 2014-09-30 Synageva Biopharma Corp. NPP1 fusion proteins
ES2798114T3 (es) 2010-03-25 2020-12-09 Univ Leland Stanford Junior Biomarcadores de proteínas y de genes para el rechazo de trasplantes de órganos
EP2683742B1 (de) 2011-03-11 2018-12-19 Alexion Pharmaceuticals, Inc. Npp1-fusionsproteine
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
US9737598B2 (en) 2014-06-30 2017-08-22 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
KR20170095367A (ko) 2014-12-19 2017-08-22 알렉시온 파마슈티칼스, 인코오포레이티드 조직 석회화의 치료 방법
JP6902185B2 (ja) 2015-11-03 2021-07-14 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Ｃｄ２００阻害剤及びその使用方法
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
WO2017218786A1 (en) 2016-06-16 2017-12-21 Alexion Pharmaceuticals, Inc. Methods of treating myointimal proliferation
CN109475603B (zh) 2016-06-20 2023-06-13 科马布有限公司 抗pd-l1抗体
KR101968246B1 (ko) * 2017-04-27 2019-04-11 서울대학교산학협력단 이종 각막 이식에서 항 cd20 단일클론항체 및 타클로리무스의 복합면역억제 방법
US11761963B2 (en) 2017-09-27 2023-09-19 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-CD200 therapy
EP3687565A1 (de) 2017-09-27 2020-08-05 Alexion Pharmaceuticals, Inc. Verfahren zur verbesserung der kardiovaskulären funktion und behandlung kardiovaskulärer erkrankungen unter verwendung einer rekombinanten ectonukleotid-pyrophosphatase-phosphodiesterase (npp1)
WO2019084682A1 (en) 2017-10-30 2019-05-09 Mcmaster University Methods for the diagnosis and treatment of endometriosis
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE170562T1 (de) * 1991-06-27 1998-09-15 Bristol Myers Squibb Co Ctl4a rezeptor, ihn enthaltenden fusionsproteine und deren verwendungen
GB9505653D0 (en) * 1995-03-21 1995-05-10 Shober Wharton Method of pest control
WO1997021450A1 (en) * 1995-12-08 1997-06-19 Brigham And Women's Hospital, Inc. Ox-2 costimulatory molecule
WO1997034633A1 (en) * 1996-03-20 1997-09-25 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
US7223729B2 (en) * 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
ES2260852T3 (es) * 1997-11-07 2006-11-01 Trillium Therapeutics Inc. Metodos y composiciones para inmunomodulacion.
US20020192215A1 (en) * 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
WO2001068697A2 (en) * 2000-03-17 2001-09-20 Gorczynski Reginald M Methods and compositions for immunoregulation
AU2002223338B2 (en) * 2000-11-22 2007-06-07 Trillium Therapeutics Inc. Truncated CD200
WO2002095030A2 (en) * 2001-05-24 2002-11-28 Trillium Therapeutics Inc. Modulation of cd200 receptors
US7196243B2 (en) * 2002-04-03 2007-03-27 Trillium Therapeutics Inc. Transgenic animal containing CD200 and uses therefor
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery

Also Published As

Publication number Publication date
US20020151485A1 (en) 2002-10-17
EP1032662B1 (de) 2006-03-08
EP1032662A1 (de) 2000-09-06
US20090232825A1 (en) 2009-09-17
CY1105364T1 (el) 2010-03-03
US20110206668A1 (en) 2011-08-25
WO1999024565A1 (en) 1999-05-20
ES2260852T3 (es) 2006-11-01
DK1032662T3 (da) 2006-07-03
AU748587B2 (en) 2002-06-06
AU1017399A (en) 1999-05-31
HK1030625A1 (en) 2001-05-11
CA2308765A1 (en) 1999-05-20
PT1032662E (pt) 2006-07-31
ATE319825T1 (de) 2006-03-15
DE69833779T2 (de) 2006-11-30
US7902151B2 (en) 2011-03-08
JP2001522867A (ja) 2001-11-20
JP4584447B2 (ja) 2010-11-24
CA2308765C (en) 2010-10-12
US20020086011A1 (en) 2002-07-04
US20020103151A1 (en) 2002-08-01
US6749854B2 (en) 2004-06-15
US6984625B2 (en) 2006-01-10
JP2010155846A (ja) 2010-07-15
US6652858B2 (en) 2003-11-25
US6338851B1 (en) 2002-01-15

Similar Documents

Publication Publication Date Title
DE69833779D1 (de) Verfahren und zusammensetzungen zur immunomodulation
ATE326239T1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
PL328858A1 (en) Immunogenous peptides
DE69010893T2 (de) Verfahren zur behandlung von koks sowie löschen desselben.
DE69833071D1 (de) Blattrahmen-IC-Karte und Verfahren zur Herstellung derselben
DE69820997D1 (de) Zusammensetzungen und verfahren zur behandlung des erhöhten augenindruckes
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
ES2216630T3 (es) Metodos de tratar la hipertension dependiente de la sal.
WO2000039280A3 (en) Leukocyte-derived interferon preparations
ATE240743T1 (de) Verfahren und substanzen gegen protozoen
DE69022926D1 (de) Virtuelle Mikrophonanlage und dafür bestimmtes Verfahren.
WO2001068697A3 (en) Methods and compositions for immunoregulation
DE69513027T2 (de) Verfahren zur bestimmung des präthrombotischen status
EP0716591A4 (de) Verfahren und Präparat zum Binden von TAU und MAP2c Proteinen
HK1071079A1 (en) Use of soluble fgl2 as an immunosuppressant
DE59408156D1 (de) Verfahren zur Herstellung und Aufarbeitung von in wässrigem Medium löslichen N-Hydroxyalkylchitosanen
ATE406178T1 (de) Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen
DE69705033T2 (de) Thioureido cyclodextrinen,insbesondere zur solubilisierung von antitumoren und antiparasitaeren mitteln und verfahren zur herstellung
DE60144493D1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
DE60134408D1 (de) Für akzessorische hiv proteine kodierende dna impfstoffe
DE3874445D1 (de) Verfahren zur herstellung von schalentierextrakt-konzentraten und schalentierextrakt-konzentrate.
ATA218497A (de) Verfahren zur extraktion von pflanzenschutzmitteln und/oder reduzierung von unerwünschten begleitstoffen
DE59600460D1 (de) Verfahren zur Herstellung von tert.-Butylamin
WO2003028537A3 (en) Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer
WO2003007800A8 (en) Methods for diagnosing and treating diseases and conditions of the digestive system and cancer

Legal Events

Date Code Title Description
8363 Opposition against the patent